证券代码：688189 证券简称：南新制药 公告编号：2025-047 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： | 回购方案首次披露日 | 2025/4/30 | | --- | --- | | 回购方案实施期限 | 2025/4/28~2026/4/27 | | 预计回购金额 | 1,000万元~2,000万元 | | 回购用途 | □减少注册资本 √用于员工持股计划或股权激励 | | | □用于转换公司可转债 | | | □为维护公司价值及股东权益 | | 累计已回购股数 | 265,516股 | | 累计已回购股数占总股本比例 | 0.10% | | 累计已回购金额 | 1,967,393.92元 | | 实际回购价格区间 | 7.02元/股~7.86元/股 | 一、回购股份的基本情况 湖南南新制药股份有限公司（以下简称"公司"）于 2025 年 4 月 28 日召开第 二届董事会第十五次会议，审议通过了《关于以集中竞价交易方式回购公司股份 方案的议案》，同意公司以不低于人民币 1,000 万元（ ...

北京大成（广州）律师事务所 关于湖南南新制药股份有限公司 2025 年第一次临时股东大会的 法律意见书 guangzhou.dachenglaw.com 广州市天河区珠江新城珠江东路 6 号广州周大福金融中心 14 层、15 层（510623） 14/F,15/F CTF Finance Centre No 6 Zhujiang East Road Tianhe District 510623, Guangzhou, China Tel:+8620-85277000 Fax:+8620-85277002 关于湖南南新制药股份有限公司 2025 年第一次临时股东大会法律意见书 北京大成（广州）律师事务所 广州市天河区珠江新城珠江东路 6 号 广州周大福金融中心 14-15 层 北京大成（广州）律师事务所 致：湖南南新制药股份有限公司 根据《中华人民共和国证券法》（以下简称"《证券法》"）、《中华人民共 和国公司法》（以下简称"《公司法》"）和中国证券监督管理委员会《上市公司 股东会规则》等法律、法规和其他有关规范性文件的要求，北京大成（广州）律 师事务所（以下简称"本所"）接受湖南南新制药股份有限公司（以下简称 ...

Market Overview - The chemical pharmaceutical sector experienced a decline of 1.67% on October 10, with Nanjing New Pharmaceutical leading the drop [1] - The Shanghai Composite Index closed at 3897.03, down 0.94%, while the Shenzhen Component Index closed at 13355.42, down 2.7% [1] Stock Performance - Notable gainers in the chemical pharmaceutical sector included: - Haizhu Yueye (Code: 001367) with a closing price of 24.42, up 4.23% [1] - Kangyi Pharmaceutical (Code: 300086) with a closing price of 7.13, up 3.78% [1] - Hanchang Group (Code: 600774) with a closing price of 9.64, up 3.77% [1] - Conversely, significant decliners included: - Nanjing New Pharmaceutical (Code: 688189) with a closing price of 8.01, down 11.98% [2] - Nuocheng Jianhua (Code: 688428) with a closing price of 24.29, down 9.16% [2] - Xiangrikui (Code: 300111) with a closing price of 6.91, down 8.60% [2] Capital Flow - The chemical pharmaceutical sector saw a net outflow of 1.305 billion yuan from institutional investors, while retail investors contributed a net inflow of 750 million yuan [2][3] - The top stocks by net inflow from institutional investors included: - Changshan Pharmaceutical (Code: 300255) with a net inflow of 117 million yuan [3] - Yipin Hong (Code: 300723) with a net inflow of 65.62 million yuan [3] - Guangsheng Tang (Code: 300436) with a net inflow of 60.34 million yuan [3]

Core Points - Hunan Nanxin Pharmaceutical Co., Ltd. has experienced a significant stock price decline, with a cumulative drop of 70% over the last 30 trading days, indicating severe abnormal trading fluctuations [2][4] - The company has confirmed that its daily operations are normal, with no significant changes in market conditions or industry policies, and no undisclosed major events [5][6] - As of October 9, 2025, the company's stock price was 9.10 yuan per share, and the rolling price-to-earnings ratio for the pharmaceutical manufacturing industry was 30.49 times, while the company's P/E ratio is negative due to a loss in audited net profit for 2024 [2][10] Abnormal Trading Situation - The stock price has deviated significantly, with a cumulative drop of 70% over 30 trading days, qualifying as severe abnormal trading according to Shanghai Stock Exchange regulations [4] Company Operations and Major Events - The company conducted a self-examination and confirmed that its daily operations are normal, with no major changes or undisclosed significant matters [5][6] - The company received a notice from the China Securities Regulatory Commission regarding a suspected violation of annual report disclosure laws, leading to an investigation [6] - The company has terminated a major asset restructuring agreement with several other pharmaceutical companies [6] Media and Market Rumors - The company has not identified any recent media reports or public rumors that could significantly impact its stock price [8] Sensitive Information - During the period of severe stock price fluctuations, there were no stock trades by the company's directors, supervisors, senior management, or controlling shareholders [9]

Core Viewpoint - Nanjing Pharmaceutical has been investigated by the China Securities Regulatory Commission (CSRC) for suspected violations of annual report disclosure regulations, which may lead to severe consequences including administrative penalties and potential delisting [1][4][5]. Company Investigation - The CSRC has issued a notice of investigation to Nanjing Pharmaceutical, indicating that the company is suspected of violating information disclosure laws [1]. - During the investigation, the company will cooperate with the CSRC and comply with relevant legal and regulatory requirements for timely disclosures [1][2]. Stock Market Reaction - Following the announcement of the investigation, Nanjing Pharmaceutical's stock hit the daily limit down, closing at 9.1 yuan per share, a decline of 19.96%, with a market capitalization of 2.5 billion yuan [3]. Financial Data Concerns - The investigation primarily focuses on the authenticity of the company's financial data, particularly a correction made in April 2025 regarding the recognition of approximately 24.54 million yuan in revenue from 2023 to 2024 [4]. - Nanjing Pharmaceutical has faced previous regulatory actions for improper accounting treatment related to sales returns, indicating ongoing issues with financial internal controls [4][5]. Performance and Financial Health - Nanjing Pharmaceutical has reported continuous losses since 2021, with revenues declining significantly in 2024, showing a drop of over 60% compared to the previous year [8][10]. - The company's revenue figures from 2021 to 2024 are 744 million yuan, 699 million yuan, 720 million yuan, and 263 million yuan, respectively, with net losses increasing to 357 million yuan in 2024 [8][10]. Product and Market Dynamics - The company's core product, Palivizumab Sodium Injection, saw a significant sales increase in 2023, reaching 667 million yuan, but faced a price drop of over 40% in 2024 due to market competition [12][13]. - The decline in sales and profitability is attributed to reduced demand for flu medications and ongoing issues with the profitability of antibiotic products, which have been under scrutiny by regulators [12][14].

证券代码：688189 证券简称：南新制药 公告编号：2025-045 湖南南新制药股份有限公司 股票交易严重异常波动公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示 1、湖南南新制药股份有限公司（以下简称"公司"）股票连续 30 个交易日 内收盘价格跌幅偏离值累计达到 70%，根据《上海证券交易所交易规则》《上海 证券交易所科创板股票异常交易实时监控细则》的有关规定，属于股票交易严重 异常波动的情形。 2、经公司自查，并向控股股东书面发函查证，公司日常经营情况正常，未 发生重大变化，市场环境或行业政策未发生重大调整，内部生产经营秩序正常。 截至本公告披露日，除公司已披露信息外，不存在其他关于公司的应披露而未披 露的重大事项。 3、截至 2025 年 10 月 9 日，公司收盘价为 9.10 元/股。根据中证指数有限 公司官网发布的数据显示，截至 2025 年 10 月 9 日，公司所属的行业分类"C27 医药制造业"最新滚动市盈率为 30.49 倍。由于 2024 年度经审计净利润为负， 因此公司股票市 ...

格隆汇10月9日｜南新制药发布异动公告，公司股票连续30个交易日内收盘价格跌幅偏离值累计达到 70%，属于股票交易严重异常波动的情形。经公司自查，并向控股股东书面发函查证，公司日常经营情 况正常，未发生重大变化，市场环境或行业政策未发生重大调整，内部生产经营秩序正常。截至本公告 披露日，除公司已披露信息外，不存在其他关于公司的应披露而未披露的重大事项。公司近日与西藏未 来生物医药股份有限公司、许昌未来制药有限责任公司和合肥市未来药物开发有限公司签署了《收购终 止协议》，交易各方一致同意终止筹划重大资产重组事项。 ...

Core Viewpoint - The company has experienced a significant stock price decline, with a cumulative drop of 70% over 30 consecutive trading days, indicating severe abnormal trading fluctuations [1] Group 1: Stock Performance - The company's stock price has deviated significantly, with a cumulative decline of 70% over the last 30 trading days, which is classified as severe abnormal trading behavior [1] - The company has conducted a self-examination and confirmed that its daily operations are normal, with no major changes occurring [1] Group 2: Business Operations - There have been no significant changes in the market environment or industry policies affecting the company [1] - The internal production and operational order of the company remains normal as of the announcement date [1] Group 3: Corporate Actions - The company has signed a "Termination Agreement" with three other pharmaceutical companies, agreeing to terminate the planned major asset restructuring [1] - The involved parties have reached a consensus to halt the major asset restructuring process [1]

Market Overview - The chemical pharmaceutical sector experienced a decline of 0.66% on October 9, with Nanjing New Pharmaceutical leading the drop [1] - The Shanghai Composite Index closed at 3933.97, up 1.32%, while the Shenzhen Component Index closed at 13725.56, up 1.47% [1] Stock Performance - Notable gainers in the chemical pharmaceutical sector included: - Haichen Pharmaceutical (300584) with a closing price of 63.81, up 13.76% and a trading volume of 155,800 shares, totaling 973 million yuan [1] - Changshan Pharmaceutical (300255) closed at 49.29, up 8.21% with a trading volume of 394,400 shares, totaling 1.916 billion yuan [1] - Conversely, Nanjing New Pharmaceutical (688189) saw a significant drop of 19.96%, closing at 9.10 with a trading volume of 32,300 shares, totaling 29.426 million yuan [2] Capital Flow - The chemical pharmaceutical sector experienced a net outflow of 1.108 billion yuan from institutional investors, while retail investors saw a net inflow of 544 million yuan [2] - The capital flow for specific stocks showed: - Changshan Pharmaceutical had a net inflow of 14.6 million yuan from institutional investors, but a net outflow of 14 million yuan from retail investors [3] - Haichen Pharmaceutical recorded a net inflow of 85.3 million yuan from institutional investors, with retail investors showing a net outflow of 68 million yuan [3]

登录新浪财经APP 搜索【信披】查看更多考评等级 南新制药（维权）(688189.SH)20cm跌停，报9.1元，总市值不足25亿元。南新制药公告称，公司近日收到中国证监会出具的《立案告知书》，因公司涉嫌年 报信息披露违法违规，中国证监会决定对公司立案。立案调查期间，公司将积极配合中国证监会的调查工作，并严格按照相关法律法规及监管要求及时履行 信息披露义务。 此外，南新制药筹划的重大资产重组也宣布告终。南新制药此前与西藏未来生物医药股份有限公司、许昌未来制药有限责任公司和合肥市未来药物开发有限 公司签署了《收购意向协议》，公司拟以现金不超过4.8亿元收购未来医药持有的标的资产组。随后，南新制药表示，公司与交易对方就本次交易的可行 性、交易方案的核心条款等进行了多次论证和磋商，但最终未能就本次交易的核心条款达成一致意见，交易各方一致同意终止筹划本次交易。(格隆汇) ...